AI-driven 3D RNA structure platform (ATOM-1) for RNA drug discovery
Atomic AI is a South San Francisco biotech founded in 2021 by Stanford AI PhD Raphael Townshend that fuses machine learning with structural biology to predict and design RNA structure. It launched publicly in January 2023 with a $35M Series A led by Playground Global (with angels including Nat Friedman and Packy McCormick), and develops ATOM-1, a foundation model for RNA structure/function used to design RNA therapeutics and RNA-targeted small molecules.
Biotech📍 South San Francisco, CAFounded 2021
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Atomic AI going public?
No. Atomic AI is private and has not filed to go public. There is no S-1 on file.
What is Atomic AI's valuation in 2026?
No confirmed valuation is on record for Atomic AI. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Atomic AI filed an S-1?
No public S-1 is on file for Atomic AI.
Who are Atomic AI's investors?
Atomic AI's investors include Playground Global, Nat Friedman, Not Boring Capital (Packy McCormick).
How much has Atomic AI raised?
Atomic AI has raised $35M in total across 1 disclosed round, most recently a Series A of $35M in Jan 2023.
Is Atomic AI publicly traded — can you buy Atomic AI stock?
No. Atomic AI is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Atomic AI on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Raphael Townshend
Founded
2021
HQ
South San Francisco, CA
Total Raised
$35M
Growth
Early platform stage; building RNA structure foundation models
Last Round
Series A — $35M (Jan 2023) · Lead: Playground Global
IPO Status
private
Fundraising Status
Series A · $35M · 3y 8mo ago
privateTotal raised $35M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series A
$35M
Jan 2023
Playground Global
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Atomic AI — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
1
via greenhouse
Product-build share
100%
engineering, research, product, design
Trajectory
steady
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 1 of 1 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Scientist, Machine Learning
Counted from Atomic AI's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Raphael Townshend
Investors
Playground Global · Nat Friedman · Not Boring Capital (Packy McCormick)
Products
ATOM-1 RNA foundation model
RNA structure & function prediction
RNA-targeted small molecules and RNA therapeutics design
Competitors
Inceptive · Therna Biosciences
BiotechRNA TherapeuticsMachine LearningTechBioAI Drug Discovery
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.